Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095212 · ClinicalTrials.gov registry record · NA
Androgen Effects in HIV-infected Women
A NA study of HIV Infection, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00095212: Completed NA study of HIV Infection, sponsored by Massachusetts General Hospital.
NCT00095212 is a NA study of HIV Infection that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095212, a NA study of HIV Infection, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Androgen deficiency in HIV-infected women is associated with sarcopenia and may cause critical reductions in physical functioning and reduced bone density. The effects of long-term androgen therapy on lean body mass, bone density and other clinical endpoints including quality of life, functional status and neurocognitive function in HIV-infected women are not known.
Primary Outcome
Represents change in measure from baseline to 18 months. 18 month mean and standard error of the mean for lean body mass measured by dual energy absorptiometry (DEXA)scan.
Conditions Studied
Interventions
- DRUG 1 Transdermal Testosterone (Patch)
- DRUG 2 Placebo Patch
Study Locations (1)
Massachusetts
- Mass General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-09 |
| Est. Completion | 2009-02 |
| Phase | NA |
What the finished NCT00095212 record still lists
NCT00095212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (90% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which 1 Transdermal Testosterone (Patch) is the first listed.
NCT00095212 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00095212 about?
NCT00095212 is a clinical study titled "Androgen Effects in HIV-infected Women". Androgen deficiency in HIV-infected women is associated with sarcopenia and may cause critical reductions in physical functioning and reduced bone density. The effects of long-term androgen therapy on lean body mass, bone density and other clinical endpoints including quality of life, functional sta...
What is the current status of trial NCT00095212?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2004-09. Estimated completion is 2009-02.
What conditions does trial NCT00095212 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00095212?
The interventions under investigation include: 1 Transdermal Testosterone (Patch) (DRUG), 2 Placebo Patch (DRUG).
Who is sponsoring clinical trial NCT00095212?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00095212 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00095212's enrollment target sits among peer trials
25 57th of 73 higher than 16 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
RECRUITING · NA
-
The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection
RECRUITING · NA
-
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
-
Technology-based Training Tool for PHAT Life
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia